Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

NY ESO 1 inhibitor

DRUG CLASS:

NY ESO 1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Melanoma	No biomarker	Melanoma	BNT111 Sensitive: B - Late Trials BNT111 Sensitive : B	BNT111 Sensitive: B - Late Trials BNT111 Sensitive : B
HLA-A*02:01	Soft Tissue Sarcoma	HLA-A*02:01	Soft Tissue Sarcoma	TAEST16001 Sensitive: C2 – Inclusion Criteria TAEST16001 Sensitive : C2	TAEST16001 Sensitive: C2 – Inclusion Criteria TAEST16001 Sensitive : C2
CTAG1B expression	Synovial Sarcoma	CTAG1B expression	Synovial Sarcoma	TBI-1301 Sensitive: C2 – Inclusion Criteria TBI-1301 Sensitive : C2	TBI-1301 Sensitive: C2 – Inclusion Criteria TBI-1301 Sensitive : C2
HLA-A*02:01 + CTAG1B expression	Soft Tissue Sarcoma	HLA-A*02:01 + CTAG1B expression	Soft Tissue Sarcoma	TAEST16001 Sensitive: C3 – Early Trials TAEST16001 Sensitive : C3	TAEST16001 Sensitive: C3 – Early Trials TAEST16001 Sensitive : C3
CTAG1B expression + CTAG2 expression	Non Small Cell Lung Cancer	CTAG1B expression + CTAG2 expression	Non Small Cell Lung Cancer	GSK3377794 Sensitive: D – Preclinical GSK3377794 Sensitive : D	GSK3377794 Sensitive: D – Preclinical GSK3377794 Sensitive : D